Hepatitis C: must address drivers of the disease, not just treatment

Interview with Dr. Mark Tyndall, infection disease specialist, Professor of Population and Public Health at the University of British Columbia, and Executive Director of the BC CDC. In a commentary published in CMAJ, Dr. Tyndall draws attention to the fact that although new treatments for hepatitis C virus are much more effective, we must not forget to address the social drivers of the disease, especially amongst people who inject drugs. IV drug users, both current and past, make up the majority in the second wave of HCV infection. Full article: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.150612To request a transcript of this podcast, contact cmajgroup@cmaj.ca

Comments or questions? Text us.

Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.

You can find Blair and Mojola on X @BlairBigham and @Drmojolaomole

X (in English): @CMAJ
X (en français): @JAMC
Facebook
Instagram: @CMAJ.ca

The CMAJ Podcast is produced by PodCraft Productions